• Indian Indices
  • Global Indices
  • Commodities
  • Currency
Sensex
  • Sensex
  • Nifty
{{x.close_price| number:2}} {{x.netchg| number:2}} ({{x.perchg | number:2}}%)
Open - {{x.open | number:2}}
Prev Close - {{x.prevclose|number:2}}
Today's High - {{x.high|number:2}}
Today's Low - {{x.low|number:2}}
Advances/Declines (30 Companies)
  • 1D
  • 1W
  • 1M
  • 1Yr
  • 5Yr
{{x.upd_time}}
FTSE 100
  • FTSE 100
  • DJIA
  • NIKKEI 225
  • HANG SENG
{{x.Date}}
{{x.close| number:2}} {{x.Chg | number:2}} ({{x.PChg | number:2}}%)
Open - {{x.close | number:2}}
Prev Close - {{x.PrevClose|number:2}}
Gold
  • Gold
  • Silver
  • Crude Oil
  • Copper
{{x.Trd_Date}} ( {{x.Time}} )
{{x.ClosePrice| number:2}} {{x.change| number:2}} ({{x.perchange | number:2}}%)
Exchange - MCX
Open - {{x.Open|number:2}}
Exp Date - {{x.Exp_Date}}
Today's High - {{x.High|number:2}}
Prev. Close - {{x.PrevClose|number:2}}
Today's Low - {{x.Low|number:2}}
USDINR
  • USDINR
  • GBPINR
  • EURINR
  • JPYINR
{{x.Lasttrdtime}} ( {{x.Time}} )
{{x.ltp| number:2}} {{x.PriceDiff| number:2}} ({{x.PerChange | number:2}}%)
Exchange - NSE
Open - {{x.Open|number:2}}
Exp Date - {{x.Expirydate}}
Today's High - {{x.High|number:2}}
Prev. Close - {{x.PrevPrice|number:2}}
Today's Low - {{x.Low|number:2}}
As On 16-Aug-2022 EOD, Market Closed
SENSEX
59,842.21
379.43 (0.64%)
NIFTY
17,825.25
127.10 (0.72%)
    No Companies Visited

Back to news list
  • Sun Pharma records loss of Rs 2,277 crore in Q4 FY22

    Sun Pharmaceutical Industries reported a consolidated net loss of Rs 2,277.25 crore in Q4 FY22 as against a net profit of Rs 894.15 crore in Q4 FY21.

    Adjusted net profit for the quarter was Rs 1,582.1 crore, up by 18% YoY, after excluding the exceptional items of Rs 3,935.7 crore & exceptional tax gain of Rs 76.4 crore. Adjusted net profit for the quarter was Rs 1,582.1 crore, up by 18% YoY, after excluding the exceptional items of Rs 3,935.7 crore & exceptional tax gain of Rs 76.4 crore. Consolidated sales from operations was at Rs 9,386.1 crore, a growth of 11% over Q4 last year. India formulation sales amounted to Rs 3,095.6 crore, up 16% over same quarter last year. US formulation sales aggregated to $389 million (up 5% YoY), Emerging Markets formulation sales were at $206 million (up 7% YoY) and Rest of World formulation sales were at $178 million (up 7% YoY).

    R&D investments fell by 2.5% to Rs 543.3 crore from Rs 557.1 crore for Q4 FY21.

    EBITDA in Q4 FY22 was Rs 2,279.7 crore, up by about 14.6% over Q4 last year, with EBITDA margin at 24.3%.

    The company's consolidated net profit increased by 12.7% to Rs 3,272.73 crore on a 15.6% rise in sales from operations to Rs 38,426.42 crore in FY22 over FY21.

    The company has repaid debt of about US$ 355 million in FY22 compared to the debt as of 31 March 2021.

    The board has proposed a final dividend of Rs 3 per share for the year FY22. This is in addition to the interim dividend of Rs 7 per share paid in FY22, taking the total dividend for FY22 to Rs 10 per share compared to Rs 7.5 per share for FY21.

    The board of Sun Pharma has approved the appointment of Dr. Pawan Goenka, independent director of the company, as the lead independent director with immediate effect.

    Further, Dilip Shanghvi has been re-appointed as the managing director for a further term of 5 years with effect from 1 April 2023 up to 31 March 2028.

    Gautam Doshi has been re-appointed as independent director for a second term of 5 years with effect from 25 May 2023 up to 24 May 2028.

    Sun Pharma is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.

    The scrip fell 1.75% to end at Rs 888.10 on the BSE today.



    Back to news list
Previous Stories :
More






Hot Pursuit News

Quick Links

Market Statistics

Formed in 1986, Capital Market Publishers India Pvt Ltd pioneered corporate databases and stock market magazine in India. Today Capitaline corporate database cover more than 35,000 listed and unlisted Indian companies. Latest technologies and standards are constantly being adopted to keep the database user-friendly, comprehensive and up-to-date.

Over the years the scope of the databases has enlarged to cover economy, sectors, mutual funds, commodities and news. Many innovative online and offline applications of these databases have been developed to meet various common as well as customized requirements.

While all the leading institutional investors use Capitaline databases, Capital Market magazine gives access to the databases to individual investors through Corporate Scoreboard. Besides stock market and company-related articles, the magazine’s independent and insightful coverage includes mutual funds, taxation, commodities and personal finance.

The power of the database is harnessed by our fired-up reporters to generate interesting ideas. The reader-friendly presentation of the idea, supplemented by relevant data and information, can be accessed online through Capita Telefolio and Telefolio Gold. These ideas are used by individual investors as well as institutional investors to do further research and stay ahead.

Capital Market Publishers India Pvt. Ltd.

401, Swastik Chambers, Sion Trombay Road, Chembur, Mumbai - 400 071.
91-22-25229720
9769005430
Kindly note www.capitalmarket.com does not send any mobile SMS, whatsapp or twitter messages
giving any kind of stock recommendations.
For Capital Market Magazine queries mail to : subscription@capitalmarket.com
For Capital Market Online Products related queries mail to : financeshop@capitalmarket.com
For any other Capital Market Website related Queries mail to : info@capitalmarket.com
To advertise on Capital Market Websites & Capital Market Fortnightly magazine mail to : advt@capitalmarket.com
Flash News 16-Aug-2022
  •  ( 15:29) Brightcom Group reports robust Q1 outcome  
  •  ( 15:07) Surya Roshni Q1 PAT drops 40% YoY to Rs 22.24 cr  
  •  ( 14:30) Oil & gas stocks in demand  
  •  ( 14:30) Shares trade with decent gains  
  •  ( 13:31) Nifty above 17,750 mark; European shares advance  
  •  ( 12:29) Honeywell Automation Q1 PAT rises 11% YoY to Rs 102 cr  
  •  ( 11:55) JK Cement Q1 PAT slips 15% YoY to Rs 162 cr  
  •  ( 11:29) Realty stocks rise for 3rd day  
  •  ( 11:28) Barometers pare some gains  
  •  ( 11:01) Unichem Labs gets US FDA nod for Schizophrenia drug  
  •  ( 10:58) Repco Home Finance Q1 PAT jumps 93% YoY to Rs 62 cr  
  •  ( 10:33) Marksans Pharma Q1 PAT slides 4% YoY  
  •  ( 09:36) KEC International bags orders worth Rs 1,313 crore  
  •  ( 08:40) Asian stocks trading higher  
  •  ( 08:02) Wockhardt initiates Phase 3 Clinical Study of novel antibiotic  
Show News
16 August 2022 00:00
3499.65
(2.15 %)
765.45
(0.66 %)
7285.60
(-0.32 %)
15914.30
(0.91 %)
703.80
(-0.85 %)
4296.90
(0.81 %)
2484.20
(1.12 %)
959.00
(0.31 %)
1501.95
(1.16 %)
2644.55
(1.90 %)
879.65
(0.56 %)
1084.25
(0.41 %)
1595.80
(0.08 %)
310.50
(0.68 %)
1846.70
(0.30 %)
1848.45
(0.24 %)
1288.40
(2.28 %)
8999.45
(3.45 %)
19697.15
(0.87 %)
158.50
(-0.03 %)
228.75
(0.42 %)
2650.55
(0.68 %)
525.90
(-0.90 %)
914.45
(0.11 %)
113.00
(0.31 %)
3392.95
(-0.20 %)
1077.85
(1.09 %)
2493.65
(0.88 %)
6653.95
(1.29 %)
437.10
(0.22 %)
Sensex 5min and Nifty 15min delayed as on .
Show Ticker
Rotate your device

Rotate your device

For the best experience please go back to portrait mode.